Eagle Pharmaceuticals, Inc. Reports Third Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Eagle Pharmaceuticals (EGRX) Tops Q3 EPS by 12c
November 9, 2016 6:51 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.77, $0.12 better than the analyst estimate of $0.65. Revenue for the quarter came in at $37.8 million versus the consensus estimate of $41.04 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... More


